Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sona Cejkova"'
Autor:
Sona Cejkova, Hana Kubatova, Filip Thieme, Libor Janousek, Jiri Fronek, Rudolf Poledne, Ivana Kralova Lesna
Publikováno v:
Cell Adhesion & Migration, Vol 13, Iss 1, Pp 292-301 (2019)
Visceral adipose tissue (VAT) may play a critical role in atherosclerotic cardiovascular disease. The goal of this study was to determine the effect of human VAT-released pro‑inflammatory cytokines on monocyte adhesion to the endothelium. The cytok
Externí odkaz:
https://doaj.org/article/d61952c012ed44cb8a41b51bdc2ed553
Publikováno v:
Journal of Lipid Research, Vol 57, Iss 10, Pp 1899-1905 (2016)
Data from experimental animal models and in vitro studies suggest that both hyperlipoproteinemia and obesity predispose to development of proinflammatory pathways of macrophages within adipose tissue. The aim of this study was to analyze whether non-
Externí odkaz:
https://doaj.org/article/85bc18ab72c549069bb35a822161e117
Autor:
Jana Šmardová, Martin Klabusay, David Potesil, Michael Doubek, Jitka Chumchalová, Marek Borsky, Dita Zezulkova, Šárka Pospíšilová, Jiri Mayer, Vera Novakova, Ludmila Rocnova, Sona Cejkova, Yvona Brychtová, Martin Trbušek
Publikováno v:
European Journal of Haematology. 82:133-142
Objectives: Abnormalities of the TP53 or ATM, cooperating tumor-suppressor genes, significantly worsen the treatment options for chronic lymphocytic leukemia (CLL) patients. Although the aberrations seem to be mutually exclusive in this leukemia, ina
Autor:
Jitka Malčíková, Miluše Svitáková, Jiri Mayer, Boris Tichy, Sona Cejkova, Martin Klabusay, Petr Kuglík, Hana Skuhrová Francová, Martin Trbušek, Ludmila Rocnova, Martin Brejcha, Michael Doubek, Šárka Pospíšilová, Vladimíra Vranová, Yvona Brychtová, Jana Šmardová
Publikováno v:
Blood. 114(26)
Deletion of TP53 gene, under routine assessment by fluorescence in situ hybridization analysis, connects with the worst prognosis in chronic lymphocytic leukemia (CLL). The presence of isolated TP53 mutation (without deletion) is associated with redu
Autor:
Jiri Mayer, Martin Trbušek, Yvona Brychtová, Šárka Pospíšilová, Michael Doubek, Sona Cejkova, Petr Kuglík, Jitka Chumchalová, Zdenek Pospisil, Jana Šmardová
Publikováno v:
Blood. 108:4973-4973
Background: Defects in the p53 gene predispose B-CLL patients for an inferior outcome, particularly a resistance to treatment by conventional chemotherapeutics. Very little data exist, however, about the efficacy of monoclonal antibody rituximab on B